- Clinical Essentials from J. Viral Hepat
- 1 comment
HCV-1b with cirrhosis: extending LDV/SOF duration tops adding RBV
ITAL-C network study also shows EU-recommended regimen is suboptimal.
Recommended on Univadis
- Clinical Essentials from Am. J. Obstet. Gynecol
- 1 comment
Society for Maternal-Fetal Medicine issues HCV guidelines
- Clinical Essentials from FDA
- 1 comment
- FULLTEXT
FDA approves olaparib maintenance therapy for ovarian cancer
- Clinical Essentials from Gen Hosp Psychiatry
- 1 comment
Anxiety and opioid misuse go hand-in-hand
- Clinical Essentials from JAMA Cardiol
- 1 comment
Which image modality is best for diagnosing myocardial ischemia?
- Clinical Essentials from J Am Acad Dermatol
- 1 comment
Meta-analysis ties psoriasis to suicide risk
- Clinical Essentials from Ann Intern Med
- 1 comment
HCV: DAA cure rates equally high with nonspecialists
- Clinical Essentials from FDA
- 1 comment
- FULLTEXT
Besponsa wins FDA approval for relapsed/refractory ALL
- Clinical Essentials from Diabetes Care
- 1 comment
Do patient portals improve diabetes outcomes?
Professional Essentials
- US Professional News
- FULLTEXT
Aid-in-dying drugs harder to come by
- Patients Will Be Asking
Should I expose my allergic child to peanuts?
- US Professional News
- FULLTEXT
Illinois pediatrician fires anti-vax parents
- US Professional News
- FULLTEXT
Connecticut physicians launch their own health information exchange
- US Professional News
- FULLTEXT
What's playing in the OR: patient song requests
- Patients Will Be Asking
Is binge watching TV bad for me?
New on Univadis
- Clinical Essentials from J Natl Compr Canc Netw
- 1 comment
Breast cancer: extended tamoxifen tops ovarian ablation/AI therapy
Lifetime outcomes are better, and costs lower, with continued tamoxifen.
- Clinical Essentials from BJU Int
- 1 comment
mpMRI tops biopsy for identifying aggressive apical prostate cancer
MRI can be useful for planning the extent of apical preservation during prostatectomy
- Clinical Essentials from Eur J Cancer
- no comment
Rare hematologic malignancies: survival outcomes in the 21st century
Unmet treatment needs persist for many malignancies.
- Clinical Essentials from Ann Surg Oncol
- 1 comment
HPV+ OPSCC: adjuvant therapy reduces recurrence risk
Adjuvant therapy improves outcomes after transoral resection.
- Vitals
- 1 comment
Heart Disease Vitals for August 2017
Embolic protection devices not so protective | The most effective HFpEF drugs | Aspirin, HF, and some Nietzsche.
- Clinical Essentials from J Clin Oncol
- 1 comment
MCRPC: low-dose cabazitaxel is safer alternative in second-line setting
PROSELICA trial compared 20 and 25 mg/m2 dosing regimens
- Clinical Essentials from J. Rheumatol
- 1 comment
- FULLTEXT
Rheumatoid arthritis: is baricitinib safe in the long term?
Results from an open-label extension trial.
- Clinical Essentials from Ann Emerg Med
- no comment
Pregnant women turning to the ED may be especially vulnerable
Is this a missed opportunity to refer and provide needed services?
- Clinical Essentials from PLoS One
- 1 comment
- FULLTEXT
Bacteremic CAP: early positive blood culture is ominous
First study addressing the issue of early TTP in pneumococcal pneumonia.
- Clinical Essentials from JAMA
- 1 comment
Does intensive lifestyle intervention enhance standard care in recent-onset type 2 diabetes?
Some possible benefit for some patients in the first decade after diagnosis.
- Clinical Essentials from PLoS One
- 1 comment
- FULLTEXT
C-reactive protein is not a useful screening test for chorioamnionitis in women with PPROM
Amniocentesis remains the gold standard.
- Clinical Essentials from Am J Gastroenterol
- 1 comment
IBS: enzyme supplement relieves symptoms
Promising results from a small study.
- Clinical Essentials from Eur Neurol
- 1 comment
- FULLTEXT
Parkinson's disease: meta-analysis confirms efficacy of adjuvant entecapone
Adding entecapone to levodopa reduces motor fluctuation in later disease.
- Clinical Essentials from Neurology
- 1 comment
Myasthenia gravis: SQ immunoglobulin quells exacerbations
Self-administered injection shows promise in phase 3 trial.